Pregnancy Increases Risk Of Transfusion Reactions
An estimated 4 million women need a blood transfusion after giving birth annually. Now new research has found that their pregnancies put these women are at
Alternative Use HemoClear Offers COVID-19 Convalescent Plasma
8 April 2020, Zwolle – In the fight against COVID-19, HemoClear’s current top priority is to help save lives, with COVID-19 convalescent plasma the
Coronavirus Epidemic Exacerbates Global Blood Shortage
The persisting coronavirus epidemic is drying up Asian blood banks, further increasing the global blood shortage. Blood supplies fail the demand for emerge
Donor Blood Transfusion Fails Young Bangladeshi Worker
How Mohammed Kamruzzaman’s blood transfusion supports the preference for autologous blood for blood transfusion Autologous blood (patients’ own blo
HemoClear Strengthens International Business Strategy
It was a pleasure to define with the experts of Task Force Healthcare and successful entrepreneur in international markets Willem van Prooijen, some valuab
Autologous Blood Leads To Better Clinical Outcomes
A patient’s own salvaged red blood cells (autologous red blood cells) are functionally superior to donated red blood cells. This is the first o
HemoClear Is Proud To Partner With Pennine Healthcare
HemoClear and Pennine Healthcare team up to develop and manufacture a complete ready-to-use HemoClear accessories kit. The kit contains all material
The World Is Experiencing a Critical Blood Shortage
Important research quantifies the global scarcity of life-saving donor blood. As a result an estimated 10 million patients unnecessarily suffer or die annu
Medista And HemoClear Partner Up
Last week at the Medica in Dusseldorf, HemoClear and Medista signed an distribution agreement. In this agreement we assign the exclusive commercial distrib
Autologous Blood Transfusion Research
We just received the results of a HemoClear study performed by EFS. The report confirms that over 99.9% of red blood cells remain well-preserved during, an
HemoClear joins forces with VDL in manufacturing the HemoClear autologous blood filter.
Hemoclear joins forces with VDL HemoClear joins forces with VDL in manufacturing the HemoClear autologous blood filter. The Dutch innovation HemoClear is t
Vincent Franssen | 26 January 2022
HemoClear re-locates production activities to the Netherlands
In the strategic ambition to optimize production, increase flexibility, and decrease lead times and costs, HemoClear will centralize all production
Vincent Franssen | 13 December 2021
New Case Report presented at BMSS2021
As a proud sponsor, HemoClear attended the Bloodless Medicine and Surgery Society Annual Meeting. At the event Dr Rosita Bihariesingh presented a case of s
Dion Osemwengie | 18 November 2021